Literature DB >> 24669351

Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia.

Christopher D Baker1, Steven H Abman1, Peter M Mourani2.   

Abstract

Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is a significant contributor to perinatal morbidity and mortality. Premature birth disrupts pulmonary vascular growth and initiates a cascade of events that result in impaired gas exchange, abnormal vasoreactivity, and pulmonary vascular remodeling that may ultimately lead to pulmonary hypertension (PH). Even infants who appear to have mild BPD suffer from varying degrees of pulmonary vascular disease (PVD). Although recent studies have enhanced our understanding of the pathobiology of PVD and PH in BPD, much remains unknown with respect to how PH should be properly defined, as well as the most accurate methods for the diagnosis and treatment of PH in infants with BPD. This article will provide neonatologists and primary care providers, as well as pediatric cardiologists and pulmonologists, with a review of the pathophysiology of PH in preterm infants with BPD and a summary of current clinical recommendations for managing PH in this population.

Entities:  

Year:  2014        PMID: 24669351      PMCID: PMC3961769          DOI: 10.1089/ped.2013.0323

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN: 2151-321X            Impact factor:   1.349


  122 in total

1.  Prospective analysis of pulmonary hypertension in extremely low birth weight infants.

Authors:  Ramachandra Bhat; Ariel A Salas; Chris Foster; Waldemar A Carlo; Namasivayam Ambalavanan
Journal:  Pediatrics       Date:  2012-02-06       Impact factor: 7.124

Review 2.  Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease.

Authors:  Bernard Thébaud; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2007-02-01       Impact factor: 21.405

3.  Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.

Authors:  D J Williamson; L L Wallman; R Jones; A M Keogh; F Scroope; R Penny; C Weber; P S Macdonald
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

4.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

5.  Inhibition of angiogenesis decreases alveolarization in the developing rat lung.

Authors:  M Jakkula; T D Le Cras; S Gebb; K P Hirth; R M Tuder; N F Voelkel; S H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-09       Impact factor: 5.464

6.  Atypical chronic lung disease patterns in neonates.

Authors:  L Charafeddine; C T D'Angio; D L Phelps
Journal:  Pediatrics       Date:  1999-04       Impact factor: 7.124

Review 7.  Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.

Authors:  Shahzad G Raja
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2012-08

Review 8.  Progress in understanding the pathogenesis of BPD using the baboon and sheep models.

Authors:  Kurt H Albertine
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

9.  Paediatric pulmonary hypertension and sildenafil: current practice and controversies.

Authors:  A J Wardle; R M R Tulloh
Journal:  Arch Dis Child Educ Pract Ed       Date:  2013-06-15       Impact factor: 1.309

Review 10.  Growth factors in the fetal and neonatal lung.

Authors:  Vasanth H Kumar; Rita M Ryan
Journal:  Front Biosci       Date:  2004-01-01
View more
  42 in total

Review 1.  Impaired pulmonary vascular development in bronchopulmonary dysplasia.

Authors:  Christopher D Baker; Steven H Abman
Journal:  Neonatology       Date:  2015-06-05       Impact factor: 4.035

2.  Using clinical and genetic data to predict pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  J K Trittmann; A Bartenschlag; E J Zmuda; J Frick; W C L Stewart; L D Nelin
Journal:  Acta Paediatr       Date:  2018-12       Impact factor: 2.299

3.  Early Pulmonary Vascular Disease in Young Adults Born Preterm.

Authors:  Kara N Goss; Arij G Beshish; Gregory P Barton; Kristin Haraldsdottir; Taylor S Levin; Laura H Tetri; Therese J Battiola; Ashley M Mulchrone; David F Pegelow; Mari Palta; Luke J Lamers; Andrew M Watson; Naomi C Chesler; Marlowe W Eldridge
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

4.  Interactive and independent effects of early lipopolysaccharide and hyperoxia exposure on developing murine lungs.

Authors:  Amrit Kumar Shrestha; Renuka T Menon; Ahmed El-Saie; Roberto Barrios; Corey Reynolds; Binoy Shivanna
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-09       Impact factor: 5.464

5.  Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.

Authors:  Rachel P Heilman; Megan B Lagoski; Keng Jin Lee; Joann M Taylor; Gina A Kim; Sara K Berkelhamer; Robin H Steinhorn; Kathryn N Farrow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-04-10       Impact factor: 4.733

6.  Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia.

Authors:  Steven H Abman; Joseph M Collaco; Edward G Shepherd; Martin Keszler; Milenka Cuevas-Guaman; Stephen E Welty; William E Truog; Sharon A McGrath-Morrow; Paul E Moore; Lawrence M Rhein; Haresh Kirpalani; Huayan Zhang; Linda L Gratny; Susan K Lynch; Jennifer Curtiss; Barbara S Stonestreet; Robin L McKinney; Kevin C Dysart; Jason Gien; Christopher D Baker; Pamela K Donohue; Eric Austin; Candice Fike; Leif D Nelin
Journal:  J Pediatr       Date:  2016-11-28       Impact factor: 4.406

Review 7.  Progress in the diagnosis and management of pulmonary hypertension in children.

Authors:  Jeremy Nicolarsen; Dunbar Ivy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

Review 8.  Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis.

Authors:  Haifeng Zhao; Phyllis A Dennery; Hongwei Yao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-04       Impact factor: 5.464

9.  Early Use of Inhaled Nitric Oxide in Preterm Infants: Is there a Rationale for Selective Approach?

Authors:  Praveen Chandrasekharan; Rafal Kozielski; Vasantha H S Kumar; Munmun Rawat; Veena Manja; Changxing Ma; Satyan Lakshminrusimha
Journal:  Am J Perinatol       Date:  2016-09-14       Impact factor: 1.862

10.  Pulmonary interstitial glycogenosis: Diagnostic evaluation and clinical course.

Authors:  Deborah R Liptzin; Christopher D Baker; Jeffrey R Darst; Jason P Weinman; Megan K Dishop; Csaba Galambos; John T Brinton; Robin R Deterding
Journal:  Pediatr Pulmonol       Date:  2018-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.